• Phase I: To determine the safety, tolerability, dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of CHR-2797 when administered orally, once daily. [ Time Frame: first 28 days of treatment ] [ Designated as safety issue: Yes ]
• Phase II: To evaluate the anti-leukaemia/myeloma effect of the recommended dose of single agent CHR-2797. [ Time Frame: End of study ] [ Designated as safety issue: No ]

• Phase I and II: To determine trough levels of CHR-2797 when administered orally, once daily, at different dose levels. [ Time Frame: End of study ] [ Designated as safety issue: Yes ]
• Phase II: To evaluate the safety and tolerability of the recommended dose of CHR-2797 when administered orally, once daily. [ Time Frame: End of study ] [ Designated as safety issue: Yes ]

This is an open-label, non-randomised, multi-centre phase I-II study of CHR-2797 administered orally once a day. The study involves two distinct phases:

• Phase I: an open-label, dose-escalating phase of the study to explore the safety, tolerability, and pharmacokinetics (PK) of CHR-2797.
• Phase II: the recommended dose level of CHR-2797, as determined in phase I, will be administered to a further cohort of approximately 40 patients to determine whether CHR-2797 has sufficient biological activity against the disease(s) under study.

This is an open-label, non-randomised, multi-centre phase I-II study of CHR-2797 administered orally once a day. The study involves two distinct phases:

Phase I: an open-label, dose-escalating phase of the study to explore the safety, tolerability, and pharmacokinetics (PK) of CHR-2797. Cohorts of 3-6 patients each will be treated with escalating, once daily, oral doses of CHR-2797 for 84 days (12 weeks), of which the first 28 days constitute the dose finding/ DLT phase. The starting dose will be 60 mg once daily. Doses will be increased in a stepwise fashion by around 40 percent per step until the MTD is reached. The proportion of patients with Multiple Myeloma will be limited to one third: one per cohort of 3 or 2 per cohort of 6. It is anticipated that 24-30 patients will be enrolled in the phase I portion of the trial. A decision will be made with regard to the disease indication to be tested in phase II (either AML/MDS or MM or both), after completion of phase I, or following definition of MTD.

Phase II: the recommended dose as determined in phase I, will be administered for 84 days to a maximum of 40 patients. The primary objective is to determine whether CHR-2797 has sufficient biological activity against the disease(s) under study. A multinomial stopping rule has been included in the design that incorporates objective responses and early progression into a decision to stop or continue this phase I/II trial. An interim assessment will be performed after 15 patients have received the maximum acceptable dose (MAD) dose of CHR-2797 with clearly defined early stopping rules.

There will be a clinical conference at the end of every cohort in the phase I portion of the study, between phase I and II and after the first 15 patients have completed therapy in phase II.

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome
• Multiple Myeloma

Inclusion Criteria:

• Signed, informed consent.
• Patients with AML, MDS (subtype RAEB-1 or RAEB-2), or MM whose disease has relapsed or is refractory to front line and/ or salvage therapy; elderly patients (≥ 60 years) with AML, MDS, MM who are not candidates for chemotherapy and for whom other therapy is inappropriate.
• Patients should have recovered from the acute adverse effects of prior therapies (excluding alopecia and grade II neuropathy).
• AML, MDS and MM are diseases of the haematopoietic system and can cause myelosuppression. Consequently supportive therapy should be given to ensure adequate values, according to local guidelines.
• A bone marrow aspirate/ biopsy performed within four weeks prior to study entry.

• Adequate bone marrow, hepatic and renal function including the following:

  1. Patients with high blast counts can be included in the trial, if they can be controlled by the use of hydroxyurea (500-3000 mg daily).
  2. Total bilirubin ≤ 1.5 x upper normal limit.
  3. AST (SGOT), ALT (SGPT) ≤ 2.5 x upper normal limit.
  4. Creatinine ≤1.5 x upper normal limit.
• Age ≥ 18 years
• Performance status (PS) ≤ 2 (ECOG scale).
• Estimated life-expectancy greater than 3 months.
• Female patients with reproductive potential must have a negative serum pregnancy test within 7 days prior to the start of the trial. A woman with reproductive potential is defined as one who is biologically capable of becoming pregnant. Patients who are not surgically sterile or postmenopausal must agree to use a medically acceptable and highly effective method of birth control for the duration of the study and to continue after the end of CHR-2797 treatment for a further 3 months (female patients) or for a further 6 months (for male patients and their partners). A highly effective method of birth control is defined as any method that results in a low failure rate, including implants, injectables, some intra-uterine devices (IUD's), sexual abstinence, and vasectomy/ sterilization. Sexually active males and females using oral contraceptive pills should also use barrier contraception. Although there is no reason to believe that the use of CHR-2797 has an effect on the pharmacokinetics of hormonal contraceptives, this has not yet been proven.

Exclusion Criteria:

• Anti-cancer therapy including chemotherapy, radiotherapy, endocrine therapy, immunotherapy or use of other investigational agents within the 4 weeks prior to trial entry- except for hydroxyurea (maximum daily dose is 3 g).
• Indolent, smouldering myeloma, monoclonal gammopathy with unknown significance.
• Patients who need a daily dose of hydroxyurea greater than 3 g to control leukocytosis.
• Co-existing active infection or serious concurrent illness.
• Any co-existing medical condition that in the investigator's judgement will substantially increase the risk associated with the patient's participation in the study
• Psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of the necessary studies.
• Gastrointestinal disorders that may interfere with absorption of the study drug.
• Patients with platelet count(s) < 20,000.
• Patients who have had a blood transfusion (platelet support or packed cells) within 7 days prior to study entry.
• Persistent grade II or greater toxicity from any cause (except haematological toxicities and peripheral neuropathy).
• Patients with grade III-IV peripheral neuropathy.
• Pregnant or breast-feeding women.